NO20013334L - Use of imidazo [1,5-A] pyrido [3,2-E] -pyrazinones as drugs - Google Patents

Use of imidazo [1,5-A] pyrido [3,2-E] -pyrazinones as drugs

Info

Publication number
NO20013334L
NO20013334L NO20013334A NO20013334A NO20013334L NO 20013334 L NO20013334 L NO 20013334L NO 20013334 A NO20013334 A NO 20013334A NO 20013334 A NO20013334 A NO 20013334A NO 20013334 L NO20013334 L NO 20013334L
Authority
NO
Norway
Prior art keywords
pyrazinones
pyrido
imidazo
phosphodiesterase
drugs
Prior art date
Application number
NO20013334A
Other languages
Norwegian (no)
Other versions
NO20013334D0 (en
Inventor
Norbert Hoefgen
Stefan Szelenyi
Marx Degenhard
Ute Egerland
Original Assignee
Dresden Arzneimittel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999102082 external-priority patent/DE19902082A1/en
Priority claimed from DE1999161302 external-priority patent/DE19961302A1/en
Application filed by Dresden Arzneimittel filed Critical Dresden Arzneimittel
Publication of NO20013334L publication Critical patent/NO20013334L/en
Publication of NO20013334D0 publication Critical patent/NO20013334D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Det er beskrevet anvendelse av imidazo[l,5-a]-pyrido[3,2-e]-pyrazinoner med formel (1) som inhibitorer av fosfodiesterase 5 for behandling av erektil dysfunksjon (impotens), anvendelsen av imidazo[l,5-a]-pyrido[3,2-e]-pyrazinoner med formel (1) som duale inhibitorer av fosfodiesterase 3 og fosfodiesterase 5 for behandling av hjerteinsufficiens, av pulmonal hypertoni og karsykdommer som starter med en redusert gjennomblødning, og fremgangsmåter for fremstilling av forbindelsene.The use of imidazo [1,5-a] pyrido [3,2-e] -pyrazinones of formula (1) as inhibitors of phosphodiesterase 5 for the treatment of erectile dysfunction (impotence), the use of imidazo [1,5 -α] pyrido [3,2-e] -pyrazinones of formula (1) as dual inhibitors of phosphodiesterase 3 and phosphodiesterase 5 for the treatment of heart failure, pulmonary hypertension and vascular disorders starting with reduced bleeding, and methods for the preparation of compounds.

NO20013334A 1999-01-20 2001-07-05 Use of imidazo [1,5-A] pyrido [3,2-E] -pyrazinones as drugs NO20013334D0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1999102082 DE19902082A1 (en) 1999-01-20 1999-01-20 New and known imidazo(1,5-a)pyrido(3,2-e)pyrazinone derivatives, useful as phosphodiesterase 5 inhibitors for treating erectile dysfunction
DE1999161302 DE19961302A1 (en) 1999-12-18 1999-12-18 Treatment of erectile dysfunction using new or known imidazo(1,5-a)pyrido(3,2-e)pyrazinones as phosphodiesterase inhibitors, some of which are also useful for treating cardiovascular disorders
PCT/EP2000/000260 WO2000043392A2 (en) 1999-01-20 2000-01-14 Use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones as medicaments

Publications (2)

Publication Number Publication Date
NO20013334L true NO20013334L (en) 2001-07-05
NO20013334D0 NO20013334D0 (en) 2001-07-05

Family

ID=26051406

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013334A NO20013334D0 (en) 1999-01-20 2001-07-05 Use of imidazo [1,5-A] pyrido [3,2-E] -pyrazinones as drugs

Country Status (23)

Country Link
EP (1) EP1144410A2 (en)
JP (1) JP2002535330A (en)
KR (1) KR20010101603A (en)
CN (1) CN1344268A (en)
AR (1) AR022318A1 (en)
AU (1) AU2291200A (en)
BG (1) BG105714A (en)
BR (1) BR0007613A (en)
CA (1) CA2296224A1 (en)
CO (1) CO5190700A1 (en)
CZ (1) CZ20012627A3 (en)
EA (1) EA200100792A1 (en)
EE (1) EE200100377A (en)
HU (1) HUP0105132A3 (en)
ID (1) ID29790A (en)
IL (1) IL144156A0 (en)
IS (1) IS5987A (en)
LT (1) LT2001078A (en)
LV (1) LV12793B (en)
NO (1) NO20013334D0 (en)
SK (1) SK10322001A3 (en)
TR (1) TR200102121T2 (en)
WO (1) WO2000043392A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
WO2003051346A2 (en) * 2001-12-17 2003-06-26 Altana Pharma Ag Use of selective pde5 inhibitors for treating partial and global respiratory failure
FR2835741B1 (en) * 2002-02-12 2006-05-05 Oreal NOVEL 6-ALCOXY-2,3-DIAMINOPYRIDINE COUPLINGS USEFUL FOR DYING KERATIN FIBERS
US6916345B2 (en) 2002-02-12 2005-07-12 L'oreal S.A. 6-alkoxy-2,3-diaminopyridine couplers for dyeing keratin fibres
DE10325813B4 (en) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxis and / or therapy in portal hypertension
JP5070052B2 (en) * 2004-08-17 2012-11-07 ザ・ジョンズ・ホプキンス・ユニバーシティ PDE5 inhibitor composition and method for treating heart disease
ES2566774T3 (en) * 2006-12-13 2016-04-15 Aska Pharmaceutical Co., Ltd. Quinoxaline derivative
JP2011505366A (en) 2007-11-30 2011-02-24 ワイス・エルエルシー Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphoesterase 10
US20090143361A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
IN2015DN02829A (en) 2011-10-10 2015-09-11 Lundbeck & Co As H
WO2013110768A1 (en) 2012-01-26 2013-08-01 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone
JP5842640B2 (en) * 2012-01-31 2016-01-13 株式会社東洋新薬 Phosphodiesterase 3 inhibitor
WO2016022836A1 (en) * 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
US9938284B2 (en) 2014-08-07 2018-04-10 Intra-Cellular Therapies, Inc. Organic compounds
BR112018000254A2 (en) 2015-07-07 2018-09-04 H Lundbeck As pde9 inhibitors with imidazotriazinone main chain and imidazopyrazinone main chain for the treatment of peripheral diseases
HUE065709T2 (en) 2018-05-25 2024-06-28 Cardurion Pharmaceuticals Inc Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-one

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
DE19510965A1 (en) * 1995-03-24 1996-09-26 Asta Medica Ag New pyrido / 3,2-e / pyrazinone with anti-asthmatic activity and process for their preparation

Also Published As

Publication number Publication date
CZ20012627A3 (en) 2002-01-16
EE200100377A (en) 2002-10-15
EP1144410A2 (en) 2001-10-17
TR200102121T2 (en) 2002-01-21
KR20010101603A (en) 2001-11-14
JP2002535330A (en) 2002-10-22
BG105714A (en) 2002-02-28
CN1344268A (en) 2002-04-10
AR022318A1 (en) 2002-09-04
IS5987A (en) 2001-06-29
IL144156A0 (en) 2002-05-23
WO2000043392A2 (en) 2000-07-27
WO2000043392A3 (en) 2000-09-28
AU2291200A (en) 2000-08-07
CO5190700A1 (en) 2002-08-29
HUP0105132A3 (en) 2002-12-28
ID29790A (en) 2001-10-11
LV12793A (en) 2002-02-20
EA200100792A1 (en) 2002-10-31
CA2296224A1 (en) 2000-07-20
LT2001078A (en) 2002-08-26
LV12793B (en) 2002-05-20
SK10322001A3 (en) 2002-07-02
NO20013334D0 (en) 2001-07-05
HUP0105132A2 (en) 2002-05-29
BR0007613A (en) 2001-10-30

Similar Documents

Publication Publication Date Title
NO20013334L (en) Use of imidazo [1,5-A] pyrido [3,2-E] -pyrazinones as drugs
WO2001087038A3 (en) β-CARBOLINE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE
WO2002064590A3 (en) Carboline derivatives
NO20024364D0 (en) Use of pyrido [3,2-E] pyrazinones as inhibitors of phosphodiesterase 5 for the treatment of erectile dysfunction
WO2005058901A8 (en) Novel 2-(piperazin-1-yl)- and 2-([1,4]diazepan-1-yl)- imidazo[4,5-d]pyridazin-4-one, production and use thereof as medicament for the treatment of diabetes mellitus
WO2002006286A3 (en) IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
WO2002064591A3 (en) Carboline derivatives
CZ20011394A3 (en) Derivative of bicyclic, nitrogen-containing heterocyclic compounds, process of its preparation and pharmaceutical preparation in which it is comprised
CA2226784A1 (en) Use of cgmp-phosphodiesterase inhibitors to treat impotence
MY140872A (en) 5,7-diaminopyrazolo[4,3-d]pyrimidines with pde-5 inhibitory activity, compositions containing such derivatives and the use of such derivatives in the treatment of hypertension and other disorders
NO310359B1 (en) Pyrrolopyrimidines and Methods for the Preparation of the Same Pharmaceutical Composition comprising the Same, Concomitant Use of the same for the Preparation of Drugs
WO2001094345A3 (en) Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
WO2002028865A3 (en) Condensed pyridoindole derivatives
WO2002000657A3 (en) Condensed pyrazindione derivatives
ATE397606T1 (en) PYRAZINO(1',2':1,6)-PYRIDO(3,4-B) INDOLE-1,4-DIONE DERIVATIVES
WO2002028859A3 (en) Condensed pyridoindole derivatives
AU2002356251A1 (en) 4-(oxazolopyridin-2-yl)-1,4-diazabicyclo-(3.2.2)nonane derivatives, preparation and therapeutic use thereof
Xia et al. Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido [1, 2-e] purin-4 (3H)-one derivatives
SI1560830T1 (en) Derivatives of (6, 7-dihydro-5h-imidazo(1,2 - a)imidazole -3 -sulfonylamino)-propionamide and their use as inhibitors upon the interaction of cams and leukointegrins
CA2372040A1 (en) Imidazodiazepine derivative
WO2002000656A3 (en) Pirazino '1$m(1)2$m(1) :1, 6! pyrido '3,4-b! indole derivatives
EA200200883A1 (en) PIRANO DERIVATIVES [2,3-C] IMIDAZO [1,2-A] PYRIDINE FOR THE TREATMENT OF GASTROINTESTINAL DISEASES
MXPA03002914A (en) Hexahydropyrazino `1 2 : 1, 6!- pyrido `3, 4-b! indole-1, 4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction.
WO2003053973A8 (en) Pyrazolyl-substituted triazoloquinoxalines
SE0100296D0 (en) New compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application